Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T21503 |
(E/Z)-Zotiraciclib
(E/Z)-TG02,(E/Z)-SB1317 |
FLT; JAK; CDK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
(E/Z)-Zotiraciclib ((E/Z)-TG02) 是一种 CDK2、JAK2和FLT3的抑制剂,IC50分别为 13、73 和 56 nM。 | |||
T62056 |
(E/Z)-Zotiraciclib hydrochloride
|
||
(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride 是有效的 CDK2,JAK2和 FLT3抑制剂。(E/Z)-Zotiraciclib 可用于癌症研究。 | |||
T63998 | (E/Z)-Zotiraciclib citrate | ||
(E/Z)-Zotiraciclib ((E/Z)-TG02) citrate 是CDK2、JAK2 和 FLT3 的有效抑制剂,能够用于研究癌症。 | |||
T70897 | Zotiraciclib HCl | ||
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, w... |